OncLive® Scientific Interchange and Workshop: Advanced, HER2+ Expressing Breast Cancer

- o Gain insight into community oncologists' opinions of efficacy and safety data on new and emerging agents for late-line treatment of advanced, HER2-expressing breast cancer
- Identify factors that influence treatment selection and planning for patients with advanced, HER2-expressing breast cancer
- O Discuss clinical challenges and areas of uncertainty faced when selecting later lines of therapy for patients with advanced, HER2-expressing breast cancer